Virginia Legislature Unanimously Approves Medical Cannabis Delivery and Labeling Reform
Virginia lawmakers have unanimously passed a bill to improve medical cannabis labeling and formally allow home delivery, streamlining patient access across the state
Key Points
- 1Virginia House and Senate both passed HB391 with unanimous votes
- 2Medical cannabis labels must now clearly state potency based on product type
- 3Licensed operators can deliver cannabis to patients’ homes, workplaces, or temporary residences
- 4The bill revises expiration date rules to better align with industry norms
In an unusual show of bipartisan unity, Virginia lawmakers voted unanimously to advance significant reforms to the state’s medical cannabis program. House Bill 391, which garnered a 99-0 vote in the House of Delegates and a 40-0 vote in the Senate, now awaits the governor’s signature. The legislation introduces clearer labeling requirements for medical cannabis products and officially authorizes home delivery to registered patients, marking a practical step forward for patient access
The new rules require that edible and topical cannabis products display potency in milligrams, while inhalable products like flower must list the total percentage of THC and CBD. This adjustment is designed to make labels more user-friendly and tailored to how patients actually consume these products. As reported by High Times, the law also clarifies that licensed operators can deliver medical cannabis directly to a patient’s home, temporary residence, or workplace, but deliveries remain prohibited at certain locations such as schools and stadiums. Employees or delivery agents who violate these regulations risk losing their authorization to transport cannabis products under the Virginia Cannabis Control Authority
Additionally, House Bill 391 changes the way expiration dates are calculated for medical cannabis products. Instead of starting the 12-month stability testing period from the date of product registration approval, it will now begin from the date the product is tested, aligning Virginia’s practices with broader industry standards. Products with longer shelf lives must present supporting testing data to justify extended expiration dates
For the cannabis industry, Virginia’s move signals that consensus is still achievable when lawmakers prioritize patient access and regulatory clarity. From the OG Lab newsroom perspective, this development highlights an important shift toward practical, patient-focused reform—even as broader debates over adult-use legalization continue. Stakeholders across the sector will be watching to see if this spirit of bipartisanship can influence future cannabis policy in Virginia and beyond